噻托溴铵联合沙美特罗/丙酸氟替卡松治疗稳定期中重度COPD的临床疗效分析

Analysis of clinical efficacy of tiotropium bromide combined with salmeterol/fluticasone propionate on moderate-severe COPD at stable stage

目的:探讨联合用药治疗稳定期中重度COPD患者的临床效果。方法:选取稳定期中重度COPD患者120例,随机分为两组。对照组单纯给予沙美特罗/丙酸氟替卡松治疗,观察组在对照组基础上给予噻托溴铵治疗。结果:观察组患者肺功能指标FVC、FEV1、FEV1%Pred、FEV1/FVC在治疗后均有明显改善,与同组治疗前和对照组治疗后比较,差异均有统计学意义(P<0.05);对照组和观察组患者6 MWT均较同组治疗前明显延长(P<0.05);治疗后两组患者圣乔治呼吸问卷(SGRQ)调查量表各因子得分均明显降低,治疗前后比较,差异具有统计学意义(P<0.05)。结论:对稳定期中重度COPD患者实施噻托溴铵联合沙美特罗/丙酸氟替卡松治疗,可以有效改善患者呼吸功能,提高患者生活质量。

Objective：To explore the clinical effect of drug combination therapy on moderate - severe COPD at stable stage. Methods ：120 patients with moderate - severe COPD at stable stage were randomly divided into the control group and the observation group. The patients in the control group were given salmetero]/fluticasone propionate, and those in the observation group were given tiotropium bromide additionally on basis of the control group. Results：The pulmonary function （ FVC, FEV1, FEVI % Prod and FEV1/FVC） of patients in the observation group were sig- nificantly improved after treatment. Compared with that in the same group before treatment and in the control group after treatment, there was signif- icant difference （ P 〈 0.05 ）. 6MWT in the two groups was significantly extended than that in the same group before treatment （ P 〈 0.05 ）. The score of each factor in the SGRQ questionnaire scale of the two groups after treatment was significantly lower, and there was significant difference in the score before and after treatment （ P 〈 0.05 ）. Conclusions： The application of tiotropium bromide combined with salmeterol / floticasone propi- onate to moderate - severe COPD at stable stage can effectively improve the respiratory function and the living quality of patients.